Seminar & Colloquium
[세미나: 10월 28일(금), 오후 1시] 인하대학교 생명과학과 손세진 교수
Title
Biomaterials-based immunoengineering strategy for cancer precision medicine
Speaker
인하대학교 생명과학과 손세진 교수
Education
- Ph.D., Department of Chemistry, Pohang University of Science and Technology (POSTECH), South Korea
- B.S., Applied Chemistry and Biotechnology, Ajou University, South Korea.
Academic career
- 2012 - 2014 Postdoctoral Fellow, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), South Korea.
- 2014 - 2017 Postdoctoral Fellow, Harvard Medical School/Brigham Women's Hospital, Boston, MA.
- 2017 - 2021 Research faculty, Department of Pharmaceutical Sciences and Biomedical Engineering, University of Michigan, Ann Arbor, MI.
| Date | Friday, October 28th, 2022
| Time | 13:00 ~
| Venue | 신소재공동연구소(131동) 제1세미나실(101호)
[Abstract]
Effective immunotherapy largely relies on the cytotoxic T lymphocytes (CTLs)-mediated elimination of cancer cells, for which the type, density, and location of CTLs in tumors determine clinical outcome. Tumors can be classified as “HOT” vs. “COLD” phenotype based on CTLs status; hot tumor is characterized by high number of CTLs in the proximity to cancer cells whereas cold tumors have few or no CTLs. Hot tumors with pre-existing CTLs are consequently more susceptible to immunotherapies, showing favorable clinical response in multiple cancers. Tumors develop physical and chemical barriers against antitumor functions of CTLs, by fostering immune-resistant tumor microenvironment (TME) that exhibit inter- and intra-tumor heterogeneity at multiple levels. Therefore, it is necessary to disrupt the immune-resistant TME to exploit the full therapeutic potential of CTLs against tumors, but such heterogeneity and complexity of TME poses numerous challenges for the field to overcome. In this talk, a new paradigm of cancer treatment with emphasis on a personalized cancer vaccine will be introduced and messenger RNA (mRNA) will be highlighted as a next generation therapeutics beyond vaccine platform. Then various immunoengineering strategies to manipulate antitumor T cells in TME will be introduced; 1) peptide-based neoantigen cancer vaccine development; 2) messenger RNA (mRNA)-based cancer vaccine development; 3) in situ vaccination strategies - photothermal therapy-induced immunogenic cell death, and mannan-based nano-PAMP to elicit anti-tumor T helper 17 (Th17) immune response in local tumors. The unique and highly multidisciplinary biomaterials-based tools and approach to precisely modulate immune responses are widely applicable to other diseases including autoimmunity, gut microbiome modulation, inflammation, and infectious diseases.
| Host | 도준상 교수 (880-1605)